Results 281 to 290 of about 98,951 (323)
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Practical Neurology, 2020
Patent foramen ovale (PFO) is the most common anatomical cause of an interatrial shunt. It is usually asymptomatic but may cause paradoxical embolism, manifesting as stroke, myocardial infarction or visceral/peripheral ischaemia. PFO is a risk factor for
Vafa Alakbarzade +4 more
semanticscholar +3 more sources
Patent foramen ovale (PFO) is the most common anatomical cause of an interatrial shunt. It is usually asymptomatic but may cause paradoxical embolism, manifesting as stroke, myocardial infarction or visceral/peripheral ischaemia. PFO is a risk factor for
Vafa Alakbarzade +4 more
semanticscholar +3 more sources
Patent foramen ovale and stroke
Journal of Neurology, 2018A patent foramen ovale (PFO) is a highly prevalent finding in cryptogenic ischaemic stroke, particularly in young adults. A common challenge in clinical practice is to distinguish between incidental and pathogenic PFO. Some clinical features and tools such as the Risk of Paradoxical Embolism score may help determining the probability of a stroke ...
Bruno Miranda +2 more
semanticscholar +4 more sources
Stroke, 2023
Patent foramen ovale (PFO) is frequently identified in young patients with ischemic stroke. Randomized controlled trials provide robust evidence supporting PFO closure in selected patients with cryptogenic ischemic stroke; however, several questions ...
L. Sposato +4 more
semanticscholar +1 more source
Patent foramen ovale (PFO) is frequently identified in young patients with ischemic stroke. Randomized controlled trials provide robust evidence supporting PFO closure in selected patients with cryptogenic ischemic stroke; however, several questions ...
L. Sposato +4 more
semanticscholar +1 more source
Incidence and time course of atrial fibrillation following patent foramen ovale closure
Catheterization and cardiovascular interventions, 2022Determine the true incidence and time course of atrial fibrillation (AF) after patent foramen ovale closure (PFOc) using implantable loop recorders (ILR) placed during cryptogenic stroke evaluation.
Yamini Krishnamurthy +3 more
semanticscholar +1 more source
Nature Reviews Disease Primers, 2016
Patent foramen ovale (PFO) is the most common congenital heart abnormality of fetal origin and is present in approximately ∼25% of the worldwide adult population. PFO is the consequence of failed closure of the foramen ovale, a normal structure that exists in the fetus to direct blood flow directly from the right to the left atrium, bypassing the ...
Shunichi, Homma +8 more
openaire +4 more sources
Patent foramen ovale (PFO) is the most common congenital heart abnormality of fetal origin and is present in approximately ∼25% of the worldwide adult population. PFO is the consequence of failed closure of the foramen ovale, a normal structure that exists in the fetus to direct blood flow directly from the right to the left atrium, bypassing the ...
Shunichi, Homma +8 more
openaire +4 more sources
Atrial fibrillation after closure of patent foramen ovale in the REDUCE clinical study
Catheterization and cardiovascular interventions, 2021To describe the occurrence of postprocedural atrial fibrillation (AF) among patients with cryptogenic stroke undergoing patent foramen ovale (PFO) closure in the REDUCE clinical study and analyze for potential risk factors for the development of ...
A. Andersen +12 more
semanticscholar +1 more source
Expert Review of Cardiovascular Therapy, 2005
Patent foramen ovale is incriminated in patients with cryptogenic stroke; however, concrete evidence that closure of patent foramen ovale using various devices is superior to continued medical therapy is not yet available. Controlled randomized trials are well underway to address this issue.
Yun-Ching, Fu, Ziyad M, Hijazi
openaire +2 more sources
Patent foramen ovale is incriminated in patients with cryptogenic stroke; however, concrete evidence that closure of patent foramen ovale using various devices is superior to continued medical therapy is not yet available. Controlled randomized trials are well underway to address this issue.
Yun-Ching, Fu, Ziyad M, Hijazi
openaire +2 more sources

